Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. lessened its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 23.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 621,840 shares of the company’s stock after selling 195,760 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.73% of Syndax Pharmaceuticals worth $8,221,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SNDX. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals in the fourth quarter valued at $26,000. Cape Investment Advisory Inc. grew its holdings in Syndax Pharmaceuticals by 157.1% in the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after purchasing an additional 3,927 shares during the last quarter. KBC Group NV grew its holdings in Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after purchasing an additional 3,559 shares during the last quarter. Optimize Financial Inc acquired a new stake in Syndax Pharmaceuticals in the fourth quarter valued at $152,000. Finally, Guggenheim Capital LLC acquired a new stake in Syndax Pharmaceuticals in the fourth quarter valued at $157,000.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the transaction, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. This represents a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is currently owned by company insiders.

Syndax Pharmaceuticals Trading Up 0.7 %

Shares of SNDX stock opened at $13.42 on Tuesday. The company has a market capitalization of $1.15 billion, a PE ratio of -3.70 and a beta of 1.28. The firm has a fifty day simple moving average of $13.05 and a 200-day simple moving average of $14.81. Syndax Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. Equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analyst Upgrades and Downgrades

SNDX has been the topic of several research reports. Citigroup reduced their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Scotiabank reduced their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).